SOURCE-LINKED STUDY SUMMARY
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.
Abstract summarizedQuality not appraised
- What was studied
- A phase 2 dose-finding trial tested the efficacy, safety, and tolerability of the dual glucagon/GLP-1 receptor agonist survodutide for obesity without diabetes.
- Who / model studied
- The trial enrolled 387 adults with BMI at least 27 kg/m² and without diabetes across 43 centers in 12 countries.
- Studied dose & schedule
- Participants received subcutaneous survodutide 0.6, 2.4, 3.6, or 4.8 mg, or placebo, once weekly for 46 weeks, including 20 weeks of dose escalation.
- What the study found
- Mean weight change was −6.2%, −12.5%, −13.2%, and −14.9% across increasing doses versus −2.8% with placebo. Adverse events occurred in 91% versus 75%; gastrointestinal events occurred in 75% versus 42%.
- Limitations & context
- Only 60.4% completed treatment. This phase 2 dose-finding trial did not test superiority to another incretin or isolate glucagon-mediated energy expenditure.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s2213-8587(23)00356-x